Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new drug clear mucus plugs in COPD lungs? trial launches.

NCT ID NCT07053423

Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dupilumab, an injectable drug, can reduce mucus plugs (blockages) in the lungs of people with moderate-to-severe COPD. About 218 current or former smokers aged 40-85 will receive either dupilumab or a placebo for 24 weeks. The main goal is to see if the drug clears mucus on CT scans and improves breathing, flare-ups, and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 218 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants with a physician diagnosis of Chronic Obstructive Pulmonary Disease (COPD) who meet the following criteria at screening: * Current or former smokers with a smoking history of ≥10 pack-years * Moderate-to-severe COPD (post-BD FEV1/FVC ratio \<0.70 and post-BD FEV1 % predicted \>30% and ≤70%) * Medical Research Council Dyspnea Scale grade ≥2 or COPD assessment test (CAT) score ≥10 * Global Initiative for Chronic Obstructive Lung Disease (GOLD) category E , Frequent or severe exacerbations * Background triple therapy (ICS + LABA + LAMA) for 3 months before randomization with a stable dose of medication for ≥1 month before Visit 1; dual therapy (LABA + LAMA) allowed if ICS is contraindicated * Evidence of Type 2 inflammation: Participants with blood eosinophils ≥300 cells/μL at screening or with blood eosinophils ≥150 cells/μL at Visit 1 (screening) and with a history of blood eosinophils ≥300 cells/μL within the past year during stable state (non-exacerbation). * Mucus score cutoff of ≥3 Exclusion Criteria: * A current diagnosis of asthma according to the Global Initiative for Asthma diagnostic (GINA) guidelines, or documented history of asthma * Significant pulmonary disease other than COPD (eg, lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome) or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts * Treatment with oxygen \>4.0 L/min for ≥8 hours/day Respiratory tract infection within 4 weeks before screening, or during the screening period * Diagnosis of α-1 anti-trypsin deficiency * Any biologic therapy (including experimental treatments and dupilumab) * Participants on treatment with mucolytics unless on stable therapy for \>6 months The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    68 sites in 19 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • American Health Research - Charlotte- Site Number : 8400013

    RECRUITING

    Charlotte, North Carolina, 28277, United States

  • Associacao Proar- Site Number : 0760005

    RECRUITING

    Salvador, Estado de Bahia, 40060-330, Brazil

  • Atrium Health Wake Forest Baptist Pulmonary, Sleep And Allergy- Site Number : 8400004

    RECRUITING

    Winston-Salem, North Carolina, 27103, United States

  • Brigham & Women's Hospital- Site Number : 8400014

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Clinical Research Associates of Central Pennsylvania- Site Number : 8400002

    RECRUITING

    DuBois, Pennsylvania, 15801, United States

  • Finlay Medical Research- Site Number : 8400010

    RECRUITING

    Miami, Florida, 33126, United States

  • Hospital Beneficência Portuguesa de São Paulo- Site Number : 0760006

    RECRUITING

    São Paulo, 01323-001, Brazil

  • Hospital Dom Pedro De Alcantara- Site Number : 0760009

    RECRUITING

    Feira de Santana, Estado de Bahia, 44001-032, Brazil

  • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760002

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90610-000, Brazil

  • Incor - Instituto do Coracao- Site Number : 0760001

    RECRUITING

    São Paulo, 05403-900, Brazil

  • Investigational Site Number : 0320001

    RECRUITING

    San Miguel de Tucumán, Tucumán Province, 4000, Argentina

  • Investigational Site Number : 0320002

    RECRUITING

    Buenos Aires, 1006, Argentina

  • Investigational Site Number : 0320003

    RECRUITING

    Buenos Aires, 1128, Argentina

  • Investigational Site Number : 1240002

    RECRUITING

    London, Ontario, N6A 5B7, Canada

  • Investigational Site Number : 1560001

    RECRUITING

    Guangzhou, 510163, China

  • Investigational Site Number : 1560004

    RECRUITING

    Hangzhou, 310009, China

  • Investigational Site Number : 1560005

    RECRUITING

    Chengdu, 610041, China

  • Investigational Site Number : 1560009

    RECRUITING

    Xiamen, 361004, China

  • Investigational Site Number : 1580001

    RECRUITING

    Kaohsiung City, 807, Taiwan

  • Investigational Site Number : 1580002

    RECRUITING

    Taipei, 10016, Taiwan

  • Investigational Site Number : 2080002

    RECRUITING

    Vejle, 7100, Denmark

  • Investigational Site Number : 2080003

    RECRUITING

    Aalborg, 9000, Denmark

  • Investigational Site Number : 2500001

    RECRUITING

    Lille, 59037, France

  • Investigational Site Number : 2500002

    RECRUITING

    Montpellier, 34090, France

  • Investigational Site Number : 2500003

    RECRUITING

    Pessac, 33604, France

  • Investigational Site Number : 2500004

    RECRUITING

    Reims, 51092, France

  • Investigational Site Number : 2500005

    RECRUITING

    Lyon, 69004, France

  • Investigational Site Number : 2500006

    RECRUITING

    Marseille, 13915, France

  • Investigational Site Number : 2500008

    RECRUITING

    La Tronche, 38700, France

  • Investigational Site Number : 3480001

    RECRUITING

    Hajdúnánás, 4080, Hungary

  • Investigational Site Number : 3480002

    RECRUITING

    Pécs, 7635, Hungary

  • Investigational Site Number : 3480003

    RECRUITING

    Debrecen, 4032, Hungary

  • Investigational Site Number : 3800001

    RECRUITING

    Cona, Ferrara, 44124, Italy

  • Investigational Site Number : 3800004

    RECRUITING

    Siena, 53100, Italy

  • Investigational Site Number : 4100001

    RECRUITING

    Seoul, Seoul-teukbyeolsi, 05030, South Korea

  • Investigational Site Number : 4100002

    RECRUITING

    Seoul, Seoul-teukbyeolsi, 06591, South Korea

  • Investigational Site Number : 4100003

    RECRUITING

    Seoul, Seoul-teukbyeolsi, 07061, South Korea

  • Investigational Site Number : 4100004

    RECRUITING

    Seoul, Seoul-teukbyeolsi, 05355, South Korea

  • Investigational Site Number : 4100005

    RECRUITING

    Anyang-si, Gyeonggi-do, 14068, South Korea

  • Investigational Site Number : 5280001

    RECRUITING

    Groningen, 9713 GR, Netherlands

  • Investigational Site Number : 5280002

    RECRUITING

    Rotterdam, 3045 PM, Netherlands

  • Investigational Site Number : 5280003

    RECRUITING

    Hoofddorp, 2134 TM, Netherlands

  • Investigational Site Number : 5280006

    RECRUITING

    Nijmegen, 6525 GA, Netherlands

  • Investigational Site Number : 6160001

    RECRUITING

    Poznan, Greater Poland Voivodeship, 60-693, Poland

  • Investigational Site Number : 6160002

    RECRUITING

    Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, 27-400, Poland

  • Investigational Site Number : 6160003

    RECRUITING

    Bialystok, Podlaskie Voivodeship, 15-044, Poland

  • Investigational Site Number : 6820003

    RECRUITING

    Riyadh, 11461, Saudi Arabia

  • Investigational Site Number : 7020001

    RECRUITING

    Singapore, 529889, Singapore

  • Investigational Site Number : 7020002

    RECRUITING

    Singapore, 308433, Singapore

  • Investigational Site Number : 7240001

    RECRUITING

    Barcelona, Barcelona [Barcelona], 08017, Spain

  • Investigational Site Number : 7240002

    RECRUITING

    Pozuelo de Alarcón, Madrid, 28223, Spain

  • Investigational Site Number : 7240003

    RECRUITING

    Madrid, 28040, Spain

  • Investigational Site Number : 7240004

    RECRUITING

    Oviedo, Principality of Asturias, 33011, Spain

  • Investigational Site Number : 7240005

    RECRUITING

    Santander, Cantabria, 39008, Spain

  • Investigational Site Number : 7520002

    RECRUITING

    Gothenburg, 413 45, Sweden

  • Investigational Site Number : 7520003

    RECRUITING

    Lund, 221 85, Sweden

  • Investigational Site Number : 7560002

    RECRUITING

    Geneva, 1205, Switzerland

  • Investigational Site Number : 7560003

    RECRUITING

    Sion, 1951, Switzerland

  • Investigational Site Number : 7560004

    RECRUITING

    Basel, 4031, Switzerland

  • Investigational Site Number : 8260001

    RECRUITING

    Bradford, BD9 6RJ, United Kingdom

  • Investigational Site Number : 8260003

    RECRUITING

    Leicester, Leicestershire, LE1 5WW, United Kingdom

  • Investigational Site Number : 8260006

    RECRUITING

    Newcastle upon Tyne, England, NE2 4HH, United Kingdom

  • Investigational Site Number : 8260008

    RECRUITING

    Southampton, Hampshire, SO16 6YD, United Kingdom

  • Johns Hopkins Bayview Medical Center- Site Number : 8400009

    RECRUITING

    Baltimore, Maryland, 21224, United States

  • Private Practice - Dr. David Kavtaradze- Site Number : 8400017

    RECRUITING

    Cordele, Georgia, 31015, United States

  • REX Clinical Trials - Beaumont- Site Number : 8400011

    RECRUITING

    Beaumont, Texas, 77701, United States

  • University of Alabama at Birmingham - School of Medicine- Site Number : 8400003

    RECRUITING

    Birmingham, Alabama, 35233, United States

  • University of Kansas Medical Center- Site Number : 8400005

    RECRUITING

    Kansas City, Kansas, 66160, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.